Integrins and haptoglobin: Molecules overexpressed in ovarian cancer

Villegas-Pineda, Julio César; Garibay‐Cerdenares, Olga Lilia; Hernández‐Ramírez, Verónica Ivonne; Gallardo‐Rincón, Dolores; León, David Cantú de; Pérez-Montiel-Gómez, María Delia; Talamás-Rohana, Patricia

doi:10.1016/j.prp.2015.10.002

Cited by 22 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, our study showed that the positive rate of Hapto expression was higher in patients with poor differentiation, lymph node metastasis, invasion of surrounding tissues/organs, and a TNM stage of III or IV and no resection. In addition, several tumor types express Hapto, and its expression correlates with poor prognosis in lung cancer, breast cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, prostate cancer, bladder cancer and ovarian cancer [11][12][13][14][15][16][17][18][19]. In this study, we found similar results that positive Hapto expression negatively correlated with overall survival and positively correlated with mortality.…”

Section: Discussionsupporting

confidence: 78%

“…Previous studies reported that Hapto may play an important role in anti-infection and anti-cancer by influencing iron metabolism of invading pathogens and tumor cells, and by affecting angiogenesis and other inflammatory processes [9,10]. Recently, several studies have revealed that the elevated cellular expressive level or serum contain of Hapto is associated with various cancers, such as lung cancer, breast cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, prostate cancer, bladder cancer and ovarian cancer [11][12][13][14][15][16][17][18][19]. Thus, Hapto might be an important marker in reflecting the malignant degrees, biological behaviors, and prognosis of some malignant lesions.…”

Section: Ivyspring International Publishermentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma

Liu

Miao

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Some studies have demonstrated that Hapto and Gremlin1 play an important biological role in many neoplasms. However, the role of Hapto and Gremlin1 in extrahepatic cholangiocarcinoma (ECC) remains to be revealed. Thus, this study investigated the prognostic and clinicopathological significance of Hapto and Gremlin1 expression in ECC. Methods: We examined Hapto and Gremlin1 expression in 100 ECC, 30 peritumoral tissues, 10 adenoma and 15 normal biliary tract tissues using EnVision immunohistochemistry. The relationship between Hapto and Gremlin 1 expression and clinicopathological parameters was evaluated using the χ 2 test or Fisher's exact test. The overall survival of patients was analyzed using Kaplan-Meier univariate survival analysis and log-rank tests. Results: Hapto and Gremlin1 proteins were overexpressed in ECC compared to peritumoral tissues, adenoma, and normal biliary tract (P<0.05 or P<0.01). The positive rate of Hapto and Gremlin1 expression was significantly higher in cases with poor differentiation, lymph node metastasis, invasion of surrounding tissues and organs, a tumor-node-metastasis (TNM) stage of III or IV and no resection. Kaplan-Meier survival analysis showed that ECC patients with positive Hapto and/or Gremlin1 expression survived significantly shorter than patients with negative Hapto and/or Gremlin1 expression. Cox multivariate analysis revealed that positive Hapto and Gremlin1 expression were independent poor prognostic factors in ECC patients. Conclusion: The present study indicated that positive Hapto and/or Gremlin1 expression are closely associated with the pathogenesis, clinical, pathological and biological behaviors, and poor prognosis in ECC.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Ivyspring International Publishermentioning

confidence: 99%

Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma

Liu

Miao

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Altered expression of several CAMs, such as mucins [ 3 , 10 ], integrins [ 11 ], CD44 [ 12 ], L1CAM [ 13 ], cadherin [ 14 ], claudins [ 15 ], EpCAM [ 16 ], ALCAM [ 17 ] and METCAM/MUC18 [ 8 , 18 , 19 ], is linked to the malignant progression of ovarian carcinoma. Some of them, such as MUC4 [ 10 ], CD44 [ 12 ], L1CAM [ 13 ], ALCAM [ 17 ] and P-cadherin [ 20 ], promote the malignant tendency of ovarian carcinoma cells.…”

Section: Cell Adhesion Molecules Involved In Regulating the Malignmentioning

confidence: 99%

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

2018

IJMS

View full text Add to dashboard Cite

METCAM/MUC18 is an integral membrane cell adhesion molecule (CAM) in the Ig-like gene super-family. It can carry out common functions of CAMs which is to perform intercellular interactions and interaction of cell with extracellular matrix in tumor microenvironment, to interact with various signaling pathways and to regulate general behaviors of cells. We and other two groups previously suggested that METCAM/MUC18 probably be utilized as a biomarker for predicting the malignant tendency of clinical ovarian carcinomas, since METAM/MUC18 expression appears to associate with the carcinoma at advanced stages. It has been further postulated to promote the malignant tendency of the carcinoma. However, our recent research results appear to support the conclusion that the above positive correlation is fortuitous; actually METCAM/MUC18 acts as a tumor and metastasis suppressor for the ovarian carcinoma cells. We also suggest possible mechanisms in the METCAM/MUC18-mediated early tumor development and metastasis of ovarian carcinoma. Moreover, we propose to employ recombinant METCAM/MUC18 proteins and other derived products as therapeutic agents to treat the ovarian cancer patients by decreasing the malignant potential of ovarian carcinoma.

show abstract

“…As such, CAMs may promote or suppress the metastatic potential of tumor cells [10]. Similar to other epithelial cancers, cell adhesion molecules must play a role in the progression of ovarian cancer, especially since aberrant expression of various CAMs, such as mucins [11], integrins [12], CD44 [13], L1CAM [14], cadherin [15], claudins [16], EpCAM [17], ALCAM [18] and METCAM/MUC18 [19,20], has been associated with the malignant progression of ovarian cancer. Some of the CAMs may play a positive role, such as MUC4 [21], CD44 [22], L1CAM [23], ALCAM [18], and P-cadherin [24]; however, some a negative role, such as β3-integrin [25], E-cadherin [26], claudin-3, 4, &7 [27], EpCAM [28], and KAI1 [29], in the progression of ovarian cancer cells.…”

Section: Cell Adhesion Molecules and The Progression Of Ovarian Cancermentioning

confidence: 99%

METCAM/MUC18 plays a Novel Tumor and Metastasis Suppressor Role in the Progression of Human Ovarian Cancer Cells

Wu¹

2017

OGIJ

View full text Add to dashboard Cite

METCAM/MUC18, an integral membrane cell adhesion molecule (CAM) in the Iglike gene super-family, is capable of performing typical functions of CAMs, such as mediating cell-cell and cell-extracellular interactions, crosstalk with intracellular signaling pathways, and modulating social behaviors of cells. The role of METCAM/ MUC18 in the progression of ovarian cancer cells has not been well studied. Previous studies showed that METCAM/MUC18 is expressed in normal ovarian epithelial cells, but expressed at higher levels in ovarian cancer tissues, suggesting that METCAM/ MUC18 may serve as a biomarker for the malignant progression of clinical ovarian cancers and it has been implicated for playing a positive role in the progression of the cancer. Recently we provided evidence from in vitro and in vivo studies to suggest that the above notion is a fortuitous correlation and that METCAM/MUC18 actually serves as a tumor and metastasis suppressor for the malignant progression of ovarian cancer cells, similar to its role in the malignant progression of one mouse melanoma cell line and nasopharyngeal carcinoma type I. Many possible mechanisms mediated by this CAM during early tumor development and metastasis are suggested. Furthermore, we suggest that METCAM/MUC18 may be used a therapeutic reagent to arrest the malignant progression of clinical ovarian cancer.

show abstract

Integrins and haptoglobin: Molecules overexpressed in ovarian cancer

Cited by 22 publications

References 26 publications

Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma

Prognostic and clinicopathological significance of Hapto and Gremlin1 expression in extrahepatic cholangiocarcinoma

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

METCAM/MUC18 plays a Novel Tumor and Metastasis Suppressor Role in the Progression of Human Ovarian Cancer Cells

Contact Info

Product

Resources

About